Active Epilepsy and Seizure Control in Adults - United States, 2013 and 2015
- PMID: 29672474
- PMCID: PMC6191103
- DOI: 10.15585/mmwr.mm6715a1
Active Epilepsy and Seizure Control in Adults - United States, 2013 and 2015
Abstract
Approximately 3 million American adults reported active epilepsy* in 2015 (1). Active epilepsy, especially when seizures are uncontrolled, poses substantial burdens because of somatic, neurologic, and mental health comorbidity; cognitive and physical dysfunction; side effects of antiseizure medications; higher injury and mortality rates; poorer quality of life; and increased financial cost (2). Thus, prompt diagnosis and seizure control (i.e., seizure-free in the 12 months preceding the survey) confers numerous clinical and social advantages to persons with active epilepsy. To obtain recent and reliable estimates of active epilepsy and seizure control status in the U.S. population, CDC analyzed aggregated data from the 2013 and the 2015 National Health Interview Surveys (NHISs). Overall, an annual estimated 2.6 million (1.1%) U.S. adults self-reported having active epilepsy, 67% of whom had seen a neurologist or an epilepsy specialist in the past year, and 90% of whom reported taking epilepsy medication. Among those taking epilepsy medication, only 44% reported having their seizures controlled. A higher prevalence of active epilepsy and poorer seizure control were associated with low family income, unemployment, and being divorced, separated, or widowed. Use of epilepsy medication was higher among adults who saw an epilepsy specialist in the past year than among those who did not. Health care and public health should ensure that adults with uncontrolled seizures have appropriate care and self-management support in order to promote seizure control, improve health and social outcomes, and reduce health care costs.
Conflict of interest statement
No conflicts of interest were reported.
Figures
Similar articles
-
Among adults with epilepsy reporting recent seizures, one of four on antiseizure medication and three of four not on medication had not seen a neurologist/epilepsy specialist within the last year, the 2010 and 2013 US National Health Interview Surveys.Epilepsy Behav. 2016 Aug;61:78-79. doi: 10.1016/j.yebeh.2016.04.031. Epub 2016 Jun 17. Epilepsy Behav. 2016. PMID: 27318431
-
Epilepsy surveillance among adults--19 States, Behavioral Risk Factor Surveillance System, 2005.MMWR Surveill Summ. 2008 Aug 8;57(6):1-20. MMWR Surveill Summ. 2008. PMID: 18685554
-
About one-half of adults with active epilepsy and seizures have annual family incomes under $25,000: The 2010 and 2013 US National Health Interview Surveys.Epilepsy Behav. 2016 May;58:33-4. doi: 10.1016/j.yebeh.2016.02.024. Epub 2016 Mar 31. Epilepsy Behav. 2016. PMID: 27039018
-
The burden of epilepsy and unmet need in people with focal seizures.Brain Behav. 2022 Sep;12(9):e2589. doi: 10.1002/brb3.2589. Epub 2022 Aug 26. Brain Behav. 2022. PMID: 36017757 Free PMC article. Review.
-
The epidemiology of epilepsy. Past, present, and future.Neurol Clin. 1996 May;14(2):383-98. doi: 10.1016/s0733-8619(05)70263-2. Neurol Clin. 1996. PMID: 8827178 Review.
Cited by
-
Disparities in Epilepsy Diagnosis and Management in High-Income Countries: A Review of the Literature.Neurol Clin Pract. 2024 Apr;14(2):e200259. doi: 10.1212/CPJ.0000000000200259. Epub 2024 Feb 8. Neurol Clin Pract. 2024. PMID: 38585438 Review.
-
The Contributions of Thrombospondin-1 to Epilepsy Formation.Neurosci Bull. 2024 May;40(5):658-672. doi: 10.1007/s12264-024-01194-2. Epub 2024 Mar 26. Neurosci Bull. 2024. PMID: 38528256 Review.
-
Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials.EClinicalMedicine. 2024 Feb 28;70:102513. doi: 10.1016/j.eclinm.2024.102513. eCollection 2024 Apr. EClinicalMedicine. 2024. PMID: 38449838 Free PMC article.
-
Factors influencing community pharmacists' knowledge about women's issues in epilepsy.Front Public Health. 2023 Sep 8;11:1251393. doi: 10.3389/fpubh.2023.1251393. eCollection 2023. Front Public Health. 2023. PMID: 37766744 Free PMC article.
-
Efficacy and Safety of Five Broad-Spectrum Antiseizure Medications for Adjunctive Treatment of Refractory Epilepsy: A Systematic Review and Network Meta-analysis.CNS Drugs. 2023 Oct;37(10):883-913. doi: 10.1007/s40263-023-01029-0. Epub 2023 Aug 17. CNS Drugs. 2023. PMID: 37589821
References
-
- Institute of Medicine. Epilepsy across the spectrum: promoting health and understanding. Washington, DC: The National Academy Press; 2012. https://www.nap.edu/read/13379/chapter/3#25 - PubMed
-
- CDC. Epilepsy in adults and access to care—United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61:909–13. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous